Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 1 · 1982–2026
Showing the 50 most relevant studies, sorted by most relevant.
S. Shi, B. Chaiwun, L. Young, et al.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 1993
I. Krupa, G. Miková, A. S. Luyt
European Polymer Journal, 2007
S. Carlquist
Stain technology, 1982
F. S. A. Majeed, N. Yusof, M. A. Suhaimi
Advances in Lightweight Materials and Structures, 2020
A. Khimchenko, C. Bikis, A. Pacureanu, et al.
Advanced Science, 2018
H. Ratech, J. Burke, D. Blayney, et al.
Cancer, 1989
Yunxia Guo, Junjie Ma, Zhengyue Li, et al.
Analytica chimica acta, 2023
Xiuyu Wang, Huseyn Gurbanov, Mehpara Adygezalova, et al.
2024
Asphaltene-resin-paraffin deposition (ARPD) is a complicated and prevalent issue in oil and gas industry, impacting the efficiency, integrity of petroleum extraction, production, transportation and processing systems. Considering all witnessed ARPD problems in Azerbaijan oil fields, this paper proposed a chemical method and optimized the type and the concentration of chemical inhibitors. And then the effect of selected chemical reagent on inhibiting the ARPD amount and thus en-hancing oil recovery was detected by reservoir simulation during both waterflooding and CO2 flooding production. Three new chemical compounds (namely, Chemical-A, Chemical-B and Chemical-C) were examined in laboratory conditions and their impact on rheological properties of high-paraffin oilfield samples of Azerbaijan (X, Y and Z) were investigated. Experimental results show that Chemical-C with concentration of 600 g/t has the best efficiency for alleviating the problems. After adding Chemical-C to the crude oil, the freezing point of oil is decreased from 12 °C to (-4) °C, ARPD amount is declined from 0.185 to 0.016 g and oil effective viscosity is reduced from 16.2 mPa·s to 3.1 mPa·s. It is determined that for water and CO2 flooding, higher injection pressure resulted in reduced asphaltene precipitation. Adding selected ARPD inhibitor, the oil recovery for waterflooding can increase from 52% to 62%, while it can rise from 55% to 68% for CO2 flooding.
Abstract licence: CC BY 4.0
Kevin A. Redosado Leon, A. Lyulin, B. Geurts
Polymers, 2024
Wijkhuijs LEA, Schmit P, Schreur-Piet I, et al.
2025
Materials for heat storage are important to fully utilize renewable energy sources and to realize a constant, on-demand supply. Organic phase change materials (PCMs) can play a crucial role in heat storage, as they have many advantages; however, their widespread commercial adoption is hindered by their low thermal conductivity and lack of cyclic stability. To enhance performance, highly thermally conductive fillers such as graphene nanoplatelets (GNPs) have been used; however, the role of the filler network has not been investigated. Here, we present, from a colloidal perspective, an in-depth study of GNP networks in paraffin PCMs. We investigate how GNP size, aspect ratio, and network topology determine thermal conductivity and cyclic stability of the composite. Our results show that the best-performing GNP network is random, with an optimized GNP aspect ratio. Filler fractions should be such that overlap between GNPs is guaranteed, which prevents leakage of paraffin from the composite, ensuring cyclic stability. These results not only contribute valuable insights into the design of new PCM composites but also emphasize the significance of considering filler geometry and network topology alongside filler type and fraction for optimizing thermal performance and cyclic stability.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.